Increased long-term bleeding complications in females undergoing endovascular revascularization for peripheral arterial disease

Marulanda, Kathleen; Duchesneau, Emilie; Patel, Sneha; Browder, Sydney E.; Caruso, Deanna; Agala, Chris B.; Kindell, Daniel G.; Curcio, Jessica; Kibbe, Melina R.; McGinigle, Katharine L.

doi:10.1016/j.jvs.2022.04.048

Cited by 5 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 18 In addition, bleeding events have been found to be more common in women compared with men for at least a year following endovascular treatment of peripheral artery disease. 19 While the population in the aforementioned studies were older, the current study by Farjat‐Pasos et al involves a younger population, with a good portion of the women likely in a pre‐ or perimenopausal stage, leading to more complicating factors in interpreting the risk of bleeding events.…”

mentioning

confidence: 80%

Cryptogenic Stroke and PFO Closure: Does Sex Matter?

Poisson,

Leppert,

Orjuela

2023

JAHA

View full text Add to dashboard Cite

mentioning

confidence: 80%

Cryptogenic Stroke and PFO Closure: Does Sex Matter?

Poisson,

Leppert,

Orjuela

2023

JAHA

View full text Add to dashboard Cite

“…The groups divided by gender were perfectly comparable for treatments. The authors speculated that different anticoagulant drug metabolisms in females may have contributed to the increase in bleeding complications, although the mechanism for this was unclear [ 11 ].…”

Section: The Risk Of Bleeding In Patients With Padmentioning

confidence: 99%

Bleeding Risk in Patients with Peripheral Arterial Disease

Visonà

Zurlo

Panzavolta

et al. 2022

Life

View full text Add to dashboard Cite

Patients with peripheral arterial disease (PAD) are at high risk of major adverse cardiac events (MACE) and major adverse limb events (MALE). Recently, antithrombotic therapies employing antiplatelet and anticoagulant drugs have proven to be valid in reducing MACE in patients with PAD and polyvascular disease and MALE, particularly in patients who have already been revascularized and remain at increased risk of MALE. However, more aggressive antithrombotic therapies lead to an increased risk of bleeding. Antithrombotic therapy and revascularization procedures entail an increased hemorrhagic risk that is also linked to having received more vigorous antithrombotic therapies. Therefore, it appears crucial to have specifically targeted scores for a PAD patient to assess bleeding and thrombotic risks. The correct utilization of a risk score will determine the variable risk factors for bleeding that can be corrected or modified, as well as identify patients at high risk that require regular reexamination and follow-up. Clinical risk scores do not represent the absolute reality, and inter-score variability must be taken into account. Moreover, several risk scores have been created to be basic and to facilitate and improve clinical decisions in daily practice. Many risk scores based on points vary according to the configuration of the studies, population type, and ethnic group, and many of the risk factor elements in a specific score are unlikely to sustain same weight for that risk. The best approach continues to be devising an uncomplicated, functional, validated, and precise score that can be adjusted to different clinical contexts and populations, while considering the mutable composition of clinical risk.

show abstract